Glaukos Corp. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
14,227.00
14,057.00
38,321.00
4,522.00
92.00
12,951
Depreciation, Depletion & Amortization
1,157.00
4,231.00
4,267.00
4,722.00
5,482.00
6,264
Other Funds
1,205.00
1,492.00
35,241.00
9,330.00
17,389.00
29,131
Funds from Operations
11,865.00
8,334.00
1,187.00
18,574.00
22,544.00
22,444
Changes in Working Capital
1,440.00
1,227.00
3,375.00
6,265.00
2,884.00
3,580
Net Operating Cash Flow
13,305.00
7,107.00
2,188.00
12,309.00
25,428.00
18,864
Capital Expenditures
852.00
868.00
877.00
6,278.00
6,311.00
Purchase/Sale of Investments
106.00
-
69,751.00
19,838.00
5,416.00
Net Investing Cash Flow
958.00
868.00
85,628.00
26,116.00
11,727.00
Issuance/Reduction of Debt, Net
-
1,850.00
9,802.00
9,696.00
-
Net Financing Cash Flow
19,257.00
3,500.00
107,110.00
1,642.00
4,667.00
Net Change in Cash
4,996.00
4,424.00
19,268.00
15,078.00
17,934.00
Free Cash Flow
14,157.00
7,975.00
3,065.00
6,031.00
19,117.00
Deferred Taxes & Investment Tax Credit
-
-
-
-
235.00
-
Net Assets from Acquisitions
-
-
15,000.00
-
-
Change in Capital Stock
19,257.00
1,650.00
116,912.00
8,054.00
4,667.00
Exchange Rate Effect
2.00
51.00
26.00
371.00
434.00

About Glaukos

View Profile
Address
229 Avenida Fabricante
San Clemente California 92672
United States
Employees -
Website http://www.glaukos.com
Updated 07/08/2019
Glaukos Corp. is an ophthalmic medical device company, which engages in the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. Its Micro Invasive Glaucoma Surgery procedures are designed to reduce intraocular eye pressure by improving aqueous outflow through the natural physiologic pathway. The company was founded by Olav B.